Neurologists and clinicians warn that GLP-1–based weight-loss medications, including semaglutide (Ozempic) and semaglutide-based treatments (such as Wegovy), may pose a risk for some people with brain or neurological disorders—particularly those with ALS. Reporting from both outlets says the concern centers on rapid weight loss. The medications can reduce appetite and lead to significant weight reduction, and experts caution that, in certain patients, losing weight quickly could be harmful. One source describes a case involving an ALS patient in which weight loss appears linked to faster disease progression. The other similarly frames the issue as a potential safety signal: neurologists say the drugs’ effects on body weight may accelerate ALS progression for some individuals. Both accounts focus on the need for medical oversight when GLP-1 drugs are used in patients with ALS or related neurological conditions, emphasizing that prescribing decisions should consider the patient’s specific risk factors and nutrition status. Neither outlet provides broad claims about all users, but both highlight that patients with ALS may require extra monitoring to prevent rapid declines in weight.